Blue Cross Blue Shield
Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.
Natera's Signatera Gains First Commercial Payor Coverage in California, Louisiana
Blue Shield of California and Blue Cross and Blue Shield of Louisiana are each covering Signatera for multiple cancer indications.
If the Center for Genomic Interpretation's in silico quality assessment catches on with payors, some labs are sure to push back or propose data sharing as an alternative.
Highmark Asks Labs for Additional Validation Data on Cancer NGS Tests; Will Other Insurers Follow?
The payor wants to see data beyond what is required through CLIA, and recommends labs use the Center for Genomic Interpretation to gauge how well tests detect and interpret variants.
Healthcare Stakeholders Redefine Cancer Multigene Testing Clinical Utility Hoping to Spur Adoption
The new definition factors in individual patients' outcomes, benefits to health systems, access to clinical trials, and shared decision making with patients.